ClinicalTrials.gg
RecruitingNCT05248243Updated Nov 13, 2023

Recruitment Assessment in Patients With Acute Respiratory Distress Syndrome and Covid-19

An observational study in Acute Respiratory Distress Syndrome, COVID-19 Pneumonia and Recruitment, sponsored by Ramos Mejía Hospital. Recruiting at 1 site in Argentina. Open to participants aged 15 Years and older. Per ClinicalTrials.gov, last updated 2023-11-13.

Sponsored by Ramos Mejía Hospital · Observational

How we know

From the registry’s dates

  • Started Mar 2022; still recruiting 4 years 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
41
Ages
15 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 21 studies in Respiratory Distress Syndrome with a site in Argentina — 6 open to participants now, 7 under way, 1 of them phase 3. Respiratory Distress Syndrome · Argentina.

Planned enrollment
6th of 12
41 · median 40
Started
2022
with 3 others
Observational
12 of 21
4 open now
Registered
13th of 21
by date
Lead sponsor
2 of 21
Ramos Mejía Hospital

Among the 21 studies in Respiratory Distress Syndrome with a site in Argentina, this one is the 6th largest by planned enrollment of the 12 observational ones that give a count, is one of 4 that started in 2022, is one of 12 observational ones, and was the 13th registered.

Respiratory Distress Syndrome

1,389 studies on the registry are indexed under Respiratory Distress Syndrome; 281 are open to participants now.

Browse Respiratory Distress Syndrome studies →

Open to participants now

6 of the 21 studies in Respiratory Distress Syndrome with a site in Argentina are open now. Recruiting first, the newest first:

All 6 open studies →

A study can be open while its sites in Argentina have not opened yet or have stopped. Only those recruiting at a site in Argentina →

Who these studies take

Of the 196 Respiratory Distress Syndrome studies recruiting now, 116 (59%) set no upper age limit and 50 (26%) stop at 75 or younger; 52 take children under 18; 9 take healthy volunteers.

This study: 15 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies in Respiratory Distress Syndrome with a site in Argentina, or all of them as a file.
02

Study summary

Respiratory failure associated with Covid-19 can be expressed as acute respiratory distress syndrome (ARDS), which is an acute inflammatory lung injury,which generally requires the use of invasive mechanical ventilation (MV). There are inconclusive results regarding the potential lung recruitment in ARDS.

At the lung level, the relationship between lung volume and pressure can be graphed through a pressure/volume (P/V) curve. In this curve, hysteresis (H) can be evaluated, which is the amount of energy generated during inspiration that is not recovered during expiration. H is related to recruitment, assuming that the greater H the greater the alveolar recruitment. For this reason, the objective of this study is the measurement of H as a way to assess the lung recruitment capacity, in patients with ARDS and in patients with Covid-19 who develop ARDS (ARDS- Covid)

Read the detailed description

During the first 7 days of the patient on mechanical ventilation (MV), measurements will be taken. For this, the patient will be in the supine position (DS) or the prone position (DP). The patient will be on a dose of analgesics, under sedation and muscle relaxation and will not present any respiratory stimulus.

Data from MV will also be recorded (prior to recruitment assessment): tidal volume (TV) in milliliters (ml), respiratory rate (RR) in a minute, fraction of inspired oxygen (FiO2), positive end-expiratory pressure (PEEP), in centimeters of water (cmH2O), plateau pressure (Pplat, measured after an end-inspiratory pause, cmH2O), mean airway pressure (PM, cmH2O), minute volume (calculated as the product of RR and TV) in milliliters per minute, ∆P (calculated as Pplat minus PEEP, cmH2O), static compliance (calculated as TV divided by ∆P, ml/cmH2O). Arterial blood gases will also be considered.

The proposed recruitment assessment will be the measurement of pulmonary hysteresis ratio. For measurements, a ventilator (Neumovent GraphNet Advance-TS, Córdoba Argentina) will be used. Additionally, a dedicated software connected to a computer will be used to perfThe evaluation of pressure in relation to volume will also be carried out, through the pressure/volume curve (PV curve), available in the respirator. A low-flow inflation and deflation PV curve from 0 up to 40 cm H2O and from 40 down to 0 cm H2O will be performed using the automatic tool on the ventilator (P/V tool; Neumovent GraphNet Advance-ts, Córdoba Argentina). The P-V curve can be visualized immediately on the screen of the mechanical ventilator and will be taken as a method to assess lung recruitment through the hysteresis-like behavior of the respiratory system. Inflation and deflation volume data will be corrected for changes in oxygen consumption.

Ratio hysteresis (RH) of the respiratory system will be measured by planimetry using SigmaPlot 12.0 software. There, through a cursor, for the measurement of hysteresis, the place where the volume was greater was drawn and the coincident pressure value was considered. Subsequently the ratio hysteresis will be calculated as the ratio between hysteresis and the product of the pressure span and the maximum volume reached (maximum hysteresis). Also, through the maximum distance between the inspiratory and expiratory limb of the curve weighted by the maximum volume, the normalized maximum distance (Vmax) is calculated. Recruitment potential will considered when there is a HR ≥ 28% and aVmax ≥ 41%.

Data Analysis. Categorical variables will be presented as number and percentage, while continuous variables will be presented as mean and standard deviation or median and interquartile range, as appropriate. The Chi2 test or Fisher's exact test will be used for qualitative variables and the Student test or the Mann-Whitney U test for quantitative variables. To evaluate correlation, the Pearson or Spearman test will be used, according to the distribution of the evaluated variables. A p ≤ 0.05 will be used.

03

Conditions studied

  • Acute Respiratory Distress Syndrome
  • COVID-19 Pneumonia
  • Recruitment
04

Who can participate

Ages eligible
15 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients 15 years of age or older who have been receiving MV in the first 7 days and have been defined as ARDS and ARDS-Covid-19 (with a positive polymerase chain reaction in nasopharyngeal swab samples) according to the clinical criteria of the Berlin definition.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients who have been receiving MV with diagnosis of ARDS (Berlin definition) and ARDS-Covid-19.

Exclusion criteria

Exclusion Criteria:

  • Patients with chronic pulmonary disease
  • Patients with a high risk of death within 3 months for reasons other than ARDS-Covid-19
  • Patients having made the decision to withhold life-sustaining treatment.
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
41 participants (estimated)
Patient registry
No

Interventions

  • ProcedureRecruitment assessment

    Intervention Details: Construction of the P/V curve with subsequent measurement of HR and Vmax.

06

What researchers measure

Primary outcomes

  1. Potential recruitment of patients with ARDS and ARDS-Covid-19

    Recruitment potential will considered when there is a HR ≥ 28% and Vmax ≥ 41%.

    Time frame: First 7 days of the patient on mechanical ventilation (MV)

Secondary outcomes

  1. Assess the association between APACHE II (Acute Physiology And Chronic Health Evaluation) score and and potential recruitment

    Assess the correlation between APACHE and potential recruitment (HR ≥ 28% and Vmax ≥ 41%). Tidal volume and pressure will be combined to report the Recruitment Index (R/I) in mL/cmH2O. A threshold of 0.5 will be used to define high recruitability (R/I ratio \>= 0.5 ml/cmH2O) and low recruitability (R/I ratio \< 0.5 ml/cmH2O).

    Time frame: First 7 days of the patient on mechanical ventilation (MV)

  2. Assess the association between TV and potential recruitment

    Assess the correlation between TV and potential recruitment (HR ≥ 28% and Vmax ≥ 41%).

    Time frame: First 7 days of the patient on mechanical ventilation (MV)

  3. Assess the association between plateau pressure and potential recruitment

    Assess the correlation between plateau pressure and potential recruitment (HR ≥ 28% and Vmax ≥ 41%). * Oxygenation: PaO2/FiO2 (ratio between arterial oxygen pressure and inspired fraction of oxygen). * Static compliance (cmH2O) * Plateau pressure (cmH2O) * ∆P (ml/cmH2O) Tidal volume and pressure will be combined to report the Recruitment Index (R/I) in mL/cmH2O.

    Time frame: First 7 days of the patient on mechanical ventilation (MV)

  4. Assess the association between ΔP and potential recruitment

    Assess the correlation between ΔP and potential recruitment (HR ≥ 28% and Vmax ≥ 41%).

    Time frame: First 7 days of the patient on mechanical ventilation (MV)

  5. Assess the association between static compliance and potential recruitment

    Assess the correlation between static compliance and potential recruitment (HR ≥ 28% and Vmax ≥ 41%).

    Time frame: First 7 days of the patient on mechanical ventilation (MV)

  6. Assess the association between mechanical power and potential recruitment

    Assess the correlation between mechanical power and potential recruitment (HR ≥ 28% and Vmax ≥ 41%).

    Time frame: First 7 days of the patient on mechanical ventilation (MV)

  7. Assess the association between PaO2/FiO2 and potential recruitment

    Assess the correlation between PaO2/FiO2 and potential recruitment (HR ≥ 28% and Vmax ≥ 41%).

    Time frame: First 7 days of the patient on mechanical ventilation (MV)

  8. Assess the association between PaCO2 and potential recruitment

    Assess the correlation between PaCO2 and potential recruitment (HR ≥ 28% and Vmax ≥ 41%).

    Time frame: First 7 days of the patient on mechanical ventilation (MV)

  9. Assess the association between ventilator free days (in days) and potential recruitment

    Assess the correlation between ventilator free days (in days) and potential recruitment (HR ≥ 28% and Vmax ≥ 41%).

    Time frame: First 7 days of the patient on mechanical ventilation (MV)

07

Study locations

1 of 1 sites recruiting
  • Hospital Agudos Ramos Mejía
    Ciudad Autonoma de Buenos Aire, Buenos Aires C1221ADC, Argentina
    Recruiting
08

References and documents

Publications

  • ARDS Definition Task Force; Ranieri VM, Rubenfeld GD, Thompson BT, Ferguson ND, Caldwell E, Fan E, Camporota L, Slutsky AS. Acute respiratory distress syndrome: the Berlin Definition. JAMA. 2012 Jun 20;307(23):2526-33. doi: 10.1001/jama.2012.5669. PubMed 22797452 ↗
  • Ziehr DR, Alladina J, Petri CR, Maley JH, Moskowitz A, Medoff BD, Hibbert KA, Thompson BT, Hardin CC. Respiratory Pathophysiology of Mechanically Ventilated Patients with COVID-19: A Cohort Study. Am J Respir Crit Care Med. 2020 Jun 15;201(12):1560-1564. doi: 10.1164/rccm.202004-1163LE. No abstract available. PubMed 32348678 ↗
  • Gattinoni L, Caironi P, Cressoni M, Chiumello D, Ranieri VM, Quintel M, Russo S, Patroniti N, Cornejo R, Bugedo G. Lung recruitment in patients with the acute respiratory distress syndrome. N Engl J Med. 2006 Apr 27;354(17):1775-86. doi: 10.1056/NEJMoa052052. PubMed 16641394 ↗
  • Marini JJ, Gattinoni L. Management of COVID-19 Respiratory Distress. JAMA. 2020 Jun 9;323(22):2329-2330. doi: 10.1001/jama.2020.6825. No abstract available. PubMed 32329799 ↗
  • Chiumello D, Arnal JM, Umbrello M, Cammaroto A, Formenti P, Mistraletti G, Bolgiaghi L, Gotti M, Novotni D, Reidt S, Froio S, Coppola S. Hysteresis and Lung Recruitment in Acute Respiratory Distress Syndrome Patients: A CT Scan Study. Crit Care Med. 2020 Oct;48(10):1494-1502. doi: 10.1097/CCM.0000000000004518. Erratum In: Crit Care Med. 2022 Mar 1;50(3):e339. doi: 10.1097/CCM.0000000000005448. PubMed 32897667 ↗
  • Demory D, Arnal JM, Wysocki M, Donati S, Granier I, Corno G, Durand-Gasselin J. Recruitability of the lung estimated by the pressure volume curve hysteresis in ARDS patients. Intensive Care Med. 2008 Nov;34(11):2019-25. doi: 10.1007/s00134-008-1167-8. Epub 2008 Jun 25. PubMed 18575846 ↗
  • Chen L, Del Sorbo L, Grieco DL, Shklar O, Junhasavasdikul D, Telias I, Fan E, Brochard L. Airway Closure in Acute Respiratory Distress Syndrome: An Underestimated and Misinterpreted Phenomenon. Am J Respir Crit Care Med. 2018 Jan 1;197(1):132-136. doi: 10.1164/rccm.201702-0388LE. No abstract available. PubMed 28557528 ↗
  • Knaus WA, Draper EA, Wagner DP, Zimmerman JE. APACHE II: a severity of disease classification system. Crit Care Med. 1985 Oct;13(10):818-29. PubMed 3928249 ↗
  • Vincent JL, de Mendonca A, Cantraine F, Moreno R, Takala J, Suter PM, Sprung CL, Colardyn F, Blecher S. Use of the SOFA score to assess the incidence of organ dysfunction/failure in intensive care units: results of a multicenter, prospective study. Working group on "sepsis-related problems" of the European Society of Intensive Care Medicine. Crit Care Med. 1998 Nov;26(11):1793-800. doi: 10.1097/00003246-199811000-00016. PubMed 9824069 ↗
  • Schoenfeld DA, Bernard GR; ARDS Network. Statistical evaluation of ventilator-free days as an efficacy measure in clinical trials of treatments for acute respiratory distress syndrome. Crit Care Med. 2002 Aug;30(8):1772-7. doi: 10.1097/00003246-200208000-00016. PubMed 12163791 ↗
  • Hohmann F, Wedekind L, Grundeis F, Dickel S, Frank J, Golinski M, Griesel M, Grimm C, Herchenhahn C, Kramer A, Metzendorf MI, Moerer O, Olbrich N, Thieme V, Vieler A, Fichtner F, Burns J, Laudi S. Early spontaneous breathing for acute respiratory distress syndrome in individuals with COVID-19. Cochrane Database Syst Rev. 2022 Jun 29;6(6):CD015077. doi: 10.1002/14651858.CD015077. PubMed 35767435 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2022 to primary completion in Mar 2023, 12 months.

Of 228 non-industry observational studies under Respiratory Distress Syndrome, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 47. This study's 12 months is below that.

Counting every sponsor, half of 234 studies reached it within 24 months; a quarter within 12 and three quarters within 49.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 15, 2022
First posted
Feb 21, 2022
StartActual
Mar 7, 2022
Primary completionActual
Mar 7, 2023
CompletionEst.
Mar 1, 2025
Last update
Nov 13, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 13, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05248243
Lead sponsor
Ramos Mejía Hospital
Responsible party
Roberto Santa Cruz (Principal Investigator, Ramos Mejía Hospital) — Principal investigator
First posted
Feb 21, 2022
Start date
Mar 7, 2022
Primary completion
Mar 7, 2023
Completion
Mar 1, 2025 (estimated)
Last update
Nov 13, 2023

Study contacts

Roberto Santa Cruz, Dr.
Contact
resc.hrrg@gmail.com
+5492966559019

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion